September 3, 2026

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takayuki Komamura, Director, Department Manager of Corporate Finance and Management Department (Telephone +81-263-25-9081)

Notice Concerning Status of Acquisition of Treasury Shares

(Acquisition of Treasury shares based on provisions of the Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act)

KISSEI PHARMACEUTICAL CO., LTD. (the "Company") announces status of acquisition of treasury shares pursuant to Article 156 of the Companies Act as applied pursuant to Article 165, Paragraph 3 of the Companies Act, which was announced on May 11, 2026, as follows.

1. Type of shares acquired: Common shares of the Company
2. Total number of shares acquired: 75,500 shares
3. Total amount of shares acquired: 303,794,000 yen
4. Period of acquisition: Started on August 1,2026 and ended on August 31,2026 (based on contract date)
5. Acquisition method: Market purchases on the Tokyo Stock Exchange based on a discretionary trading contract regarding acquisition of own shares

(Reference)

1. Details of the resolution at the meeting of Board of Directors held on May 11, 2026
   1) Type of shares to be acquired: Common shares of the Company
   2) Total number of shares to be acquired: Up to 1,300,000 shares
      (Percentage of total number of issued shares (excluding treasury shares) :3.14%)
   3) Total acquisition cost: 6 billion yen (maximum)
   4) Acquisition period: From May 12,2026 to December 31, 2026
   5) Acquisition method: Market purchases on the Tokyo Stock Exchange
      1. Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
      2. Market purchases based on a discretionary trading contract regarding acquisition of own shares

2. Cumulative number and value of own shares acquired so far based on the above resolution at the Board of Directors meeting (As of August 31,2026)
   1) Total number of shares acquired: 75,500 shares
   2) Total amount of shares acquired: 303,794,000 yen

-End-